WHO Grants Emergency Use Listing for Sinovac COVID-19 Vaccine... Second Chinese Vaccine

[Image source=AP Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] The World Health Organization (WHO) has approved the emergency use of the COVID-19 vaccine developed by the Chinese pharmaceutical company Sinovac. This is the second Chinese-made COVID-19 vaccine to receive WHO emergency use approval, following Sinopharm last month.

On the 1st (local time), WHO issued a statement recommending that the Sinovac vaccine be administered twice to adults aged 18 and over, with an interval of 2 to 4 weeks between doses.

WHO explained, "The Sinovac vaccine has a 51% efficacy in preventing symptomatic disease and is 100% effective in preventing severe cases and hospitalization."

With the Sinovac vaccine receiving WHO emergency use approval, it can be distributed through COVAX, the international project for the joint procurement and distribution of COVID-19 vaccines.

In addition to Sinovac, WHO has approved the emergency use of vaccines from Sinopharm, Pfizer, Moderna, AstraZeneca, and Johnson & Johnson (J&J/Janssen).

Peng Duojia, chairman of the China Vaccine Industry Association (CVIA), told the Chinese state media Global Times, "This decision demonstrates that China not only has the willingness and means to help the world combat infectious diseases but also the capability to do so."

This content was produced with the assistance of AI translation services.